(Press-News.org) An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.
The research, published in BMC Medicine and funded by Cancer Research UK, found that an additional 3.3 million people said they would be interested in using weight loss drugs over the next year.
The team looked at data from 5,260 people who were representative of the general population and who responded to a survey conducted in early 2025.
They found that use of the drugs was twice as common among women compared to men and more common among people in middle age (aged 45-55), and those who reported psychological distress in the past month.
The team also found that levels of use were similar across social grades, but that interest in using drugs to support weight loss in future was greater among more typically disadvantaged groups (among whom obesity is more prevalent), suggesting a demand not currently met by private prescriptions.*
Lead author Professor Sarah Jackson, from the UCL Institute of Epidemiology & Health Care, said: “Our findings show that an estimated 4.9 million adults in Great Britain – nearly one in 10 – have recently used a drug to support weight loss or were interested in using one in the near future.
“This usage far exceeds NHS England’s initial goal of prescribing these drugs to 220,000 people over three years.
“We do not know about our survey respondents’ BMI or health conditions, so it is not clear how far this reflects a genuine medical need or how often the drugs are used unnecessarily by people of a healthy weight.
“We hope to gather more detailed data in future, monitoring how trends change over time. Good data are important as large numbers of people are taking these drugs outside medical supervision and there is wide potential for misuse. NHS prescribing data only captures a small part of the picture.”
Co-author Professor Clare Llewellyn (UCL Institute of Epidemiology & Health Care) said: “Weight-loss drugs like GLP-1 agonists could play an important role in improving the health of the nation. Our findings suggest many people are accessing these medications outside the NHS. This raises concerns about equity given the costs of these drugs, as well as the adequacy of supervision of treatment.”
For the study, researchers used data from the Smoking Toolkit Study, an ongoing survey that interviews a different sample of adults in England, Wales and Scotland (but not Northern Ireland) each month, who are representative of the country’s general population. Questions relating to weight loss medications were added to three months of questionnaires (January-March 2025).
Survey participants aged 18 and over were asked about their use of five medications: Mounjaro (containing tirzepatide), Ozempic, Wegovy, Rybelsus (all three containing semaglutide) and Saxenda (containing liraglutide).** Most respondents taking medication solely for weight loss (four out of five) reported using Mounjaro.
Overall, 4.5% of participants reported using one of the medications in the past year for any reason; 2.9% reported using them for weight loss (i.e., an estimated 1.6 million people), while 1.7% reported using them exclusively for weight loss (equivalent to 910,000 people) i.e., they did not use them for an additional reason such as to lower heart disease risk or regulate blood sugar levels for type 2 diabetes.
Use of the medications to support weight loss was higher among women than men (4% vs 1.7%) and higher among those of middle age (4.2% of 45- and 55-year-olds compared to 1.2% of 18-year-olds and 1.5% of 75-year-olds***).
Prevalence was higher among those who reported moderate or severe psychological distress in the past month (3.7% vs. 2.4% among those reporting no/low distress).
Among those using medication for weight loss, 15% (about one in seven) were using medication not licensed for this purpose (such as Rybelsus licensed in the UK for type 2 diabetes only).
Using drugs “off-label” can also pose safety risks, the researchers said, if the medicines are accessed without appropriate clinical supervision.
Interest in using drugs to support weight loss in future was reported by 6.5% of respondents who had not used a medication for weight loss in the past year (equivalent to 3.3 million). Interest was higher among women, with nearly one in 10 (8.9%) saying they would be likely or very likely to consider using them in the next year, and among people aged 45 to 55 (9.7%).
By contrast, only one in 20 (5.1%) men said they would likely consider using weight loss medications in the next year.
Interest was also higher among people who had experienced moderate or severe psychological distress in the past month (10.0% vs. 5.2% among those reporting no or low distress).
Jo Harby, Director of Health Information at Cancer Research UK, said: “As obesity rates rise in the UK, this study shows growing public interest in weight loss medication. While these drugs can aid weight loss, they’re not a silver-bullet, as evidence suggests most people regain weight after treatment.
“More research is needed on their long-term impact, how these drugs affect cancer risk, and how best to support people to maintain a healthy weight. These drugs should only be prescribed by healthcare professionals alongside continued care and advice on diet and activity. It’s also vital that everyone who needs it can access a range of weight-management support.
“The world around us shapes our health, and the UK Government must do more to create healthier environments for all.”
* Mounjaro, for instance, typically costs £200 a month so is unaffordable for many.
** All of these medications function as appetite suppressants by mimicking a hormone (GLP-1, or glucagon-like peptide-1) which makes people feel fuller. Mounjaro, in addition, also helps regulate blood sugar levels by mimicking the hormone GIP (glucose-dependent insulinotropic polypeptide).
***These estimates of specific ages are based on modelling drawing on data from participants of all ages.
END
1.6 million UK adults used weight loss drugs in past year
2026-01-08
ELSE PRESS RELEASES FROM THIS DATE:
American College of Cardiology comments on new dietary guidelines for Americans
2026-01-07
American College of Cardiology President Christopher M. Kramer, MD, FACC, issued the following statement on the release of new Dietary Guidelines for Americans by the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture.
“The ACC acknowledges and appreciates the release of new federal nutrition guidance and remains committed to helping clinicians and patients use it to support heart health,” said ACC President Christopher M. Kramer, MD, FACC.
“We welcome the inclusion of several important science-based recommendations, ...
American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator partner to advance and commercialize promising rare disease treatments
2026-01-07
MILWAUKEE, WI and CAMBRIDGE, MA – January 7, 2026 – The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling access to stalled rare disease treatments, today announced a partnership to establish CGTxchange, a jointly owned entity that will serve as a clearinghouse and marketplace for deprioritized CGTs.
The new joint venture will address a growing and urgent challenge facing the CGT field: policy and economic shifts in ...
One in 14 patients having day case surgery have new or worse chronic pain 3 months after their operation
2026-01-07
Two new studies published in Anaesthesia (the journal of the Association of Anaesthetists) analysing pain and other factors connected with day surgery in the UK show that around 1 in 8 patients having day-case surgery end up not going home and instead are admitted to hospital for various complications. Furthermore, one in 14 go on to develop chronic pain at the operative site after the procedure.
The studies are by Dr Martha Belete, Torbay and South Devon NHS Foundation Trust, Torbay, Devon, UK and Dr Adam Brayne, University Hospitals Plymouth NHS Trust, ...
New study highlights link between eviction rates and gun violence
2026-01-07
Violent crime has fallen to historic lows in Chicago, although gun violence continues to plague neighborhoods with concentrated poverty. A 2023 study of five major cities showed that more than 55% of shootings occurred in just 9% of total census tracts, and that small increases in things like poverty, unemployment, or limited access to health care are associated with large increases in firearm violence.
Yet not every neighborhood that struggles with these challenges also has high rates of violence. ...
Heatwaves heat up soil but not toxin levels in rice, study finds
2026-01-07
In a surprising twist amid rising climate concerns, new research shows that scorching soil temperatures during extreme heatwaves do not necessarily boost the uptake of toxic elements like arsenic in rice crops. This finding, from a real world experiment during China's record breaking 2022 heatwaves, challenges fears that global warming will poison staple foods.
"Our study reveals that soil warming alone, decoupled from air temperature rises, does not inevitably ramp up arsenic or heavy metal accumulation in rice grains," said Sha Zhang, ...
Digital modeling reveals where construction carbon emissions really come from
2026-01-07
A new study shows how digital building models can be used to pinpoint where carbon emissions occur across a building’s entire life cycle, offering designers and policymakers a powerful tool to reduce the climate footprint of the construction industry.
Researchers developed an integrated method that combines Building Information Modeling and Life Cycle Assessment to calculate carbon emissions from the earliest design stage through construction, operation, and eventual demolition. Using a real office building in China as a case study, the team demonstrated how emissions can be quantified in detail and how targeted reduction ...
Turning farm waste into water filters
2026-01-07
Researchers at the University of Delaware have transformed discarded corn cobs and other agricultural byproducts into high performance biochar filters that capture both ammonia and tiny plastic particles from water. In laboratory tests, optimized biochar removed up to 64 percent of dissolved ammonia and more than 97 percent of polystyrene micro and nanoplastics without leaching harmful chemicals back into the water. The study points to a practical way to clean polluted water while recycling agricultural waste and locking ...
New study shows how the spleen helps the immune system accept a transplant
2026-01-07
MINNEAPOLIS/ST. PAUL (1/07/2026) —New research from the University of Minnesota Medical School offers a new view of how the immune system responds to organ transplants. The findings, published today in Science Advances External link that opens in the same window, show that T cell exhaustion – traditionally viewed as a pathological failure of the immune system — can instead play a protective role by helping the body tolerate a donated organ.
The study identifies the spleen as a key control center for transplant tolerance. Researchers found that administering apoptotic donor leukocytes (ADLs) triggers the expansion of donor-specific regulatory T cells, ...
New Mayo Clinic study advances personalized prostate cancer education with an EHR-integrated AI agent
2026-01-07
PHOENIX — Mayo Clinic researchers have developed and evaluated MedEduChat, an electronic health record (EHR) that works with a large language model to provide accurate, patient-specific prostate cancer education.
The findings are published in Nature Portfolio Digital Medicine and highlight a new approach to delivering timely, individualized guidance for people navigating a prostate cancer diagnosis.
Cancer patients often face uncertainty as they process complex information about their diagnosis and treatment options. Limited time with ...
Researchers identify novel therapeutic target to improve recovery after nerve injury
2026-01-07
Peripheral nerve injury reduces the ability of macrophages to clear dead or dying cells – a process known as efferocytosis – leading to chronic pain
Restoring efferocytosis ability reduced neuropathic pain in lab models
Efferocytosis is a potential therapeutic target for chronic neuropathic pain
Researchers at The University of Texas MD Anderson Cancer Center have discovered that targeting a specific immune process could help improve recovery after nerve injury and reduce chronic pain.
The study, published in Proceedings of the National Academy of Sciences (PNAS), was led by Peter Grace, Ph.D., associate ...